The treatment recommendations for low-density lipoprotein cholesterol (LDL-C) have been intensified in the 2019 European guidelines for the management of dyslipidemias.1 In very high-risk patients, including those with established cardiovascular disease (CVD), a LDL-C reduction of ≥50% from baseline and a LDL-C goal of <1.4 mmol/L received a class 1A recommendation.1 The guidelines recommend starting proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with an acute...